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Background: The clinical benefits of bioimpedance spectroscopy (BIS)-guided fluid management in patients on
hemodialysis have been widely demonstrated. However, no previous reports have evaluated the effect of regular
and serial BIS-guided fluid management on the residual renal function (RRF) in patients on peritoneal dialysis (PD).
Therefore, we will evaluate the clinical efficacy of BIS-guided fluid management for preserving RRF and protecting
cardiovascular events in patients on PD.
Methods/design: This is a multicenter, prospective, randomized controlled trial. A total of 138 participants on PD
will be enrolled and randomly assigned to receive either BIS-guided fluid management or fluid management based
only on the clinical information for 1 year. The primary outcome is the change in the glomerular filtration rate (GFR)
between months 0 and 12 after starting treatment. The secondary outcomes will include GFR at month 12, time to
the anuric state (urine volume <100 ml/day), and fatal and nonfatal cardiovascular events during treatment.
Discussion: This is the first clinical trial to investigate the effect of BIS-guided fluid management on RRF and for
protecting against cardiovascular events in patients on PD.
Trial registration: Clinical Trials.gov number NCT01887262, June 24, 2013.
Keywords: Fluid balance, Bioimpedance spectroscopy, Peritoneal dialysisBackground
Overhydration (OH) is common, and is associated with
cardiac dysfunction and mortality in patients on peritoneal
dialysis (PD) [1,2]. By contrast, volume depletion is associ-
ated with a more rapid loss of residual renal function
(RRF) in patients on PD [3]. Therefore, euvolemia is one
of the prime objectives in these patients.
In clinical practice, the volume status is indirectly
assessed using various clinical data, including edema,
weight gain, and hypertension [4]. Although there is a
linear relationship between blood pressure (BP) and* Correspondence: kyna@snubh.org
†Equal contributors
1Department of Internal Medicine, Seoul National University Bundang
Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam 463-707,
Gyeonggi-do, South Korea
Full list of author information is available at the end of the article
© 2014 Baek et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.tissue hydration, a substantial proportion of patients do
not follow that pattern. A number of patients who are
euvolemic or underhydrated have systolic hypertension.
Volume reduction to control systolic hypertension may
result in dehydration in these patients, which may
decrease RRF or compromise coronary artery perfusion,
and may result in acute myocardial infarction [5]. Con-
versely, patients with congestive heart failure may have a
low or normal BP despite OH. Therefore, BP cannot
reflect changes in the hydration status [2].
Bioimpedance spectroscopy (BIS) has been used to
measure the water compartment of the body [6]. In pa-
tients on dialysis, body composition, including extracellular
water (ECW) and intracellular water (ICW), muscle mass,
and fat mass, changes slowly over several months. Regular
monitoring of body composition using BIS can facilitated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dialysis.
The purpose of the present study is to evaluate the
clinical usefulness of BIS-guided fluid management for
preserving RRF and protecting against cardiovascular
events in patients on PD.
Methods/design
Hypothesis
BIS-guided fluid management will preserve RRF in pa-
tients on PD better than fluid management guided by
clinical information alone, such as BP, body weight
(BWT), and physical examination results.
Study design
The study is a multicenter, prospective, parallel-group,
open-label, randomized controlled trial. It is an
investigator-initiated clinical trial. The study algorithm
is depicted in Figure 1. After enrollment, clinical
follow-up will be performed after 0, 2, 4, 6, 8, 10, and
12 months of treatment.
Study participants and measurements
All patients will be selected from the outpatient renal
clinic of five tertiary hospitals in Korea (Seoul National
University Bundang Hospital, Seoul National University
Hospital, Seoul National University Boramae Medical
Center, Gachon University Gil Hospital, and Wonju
Severance Christian Hospital). Patients aged 20 to 75 years
who are on PD and have a daily urine output of more than
500 ml will be screened [7]. The following tasks will be
conducted at the initial visit: 1) completion of question-
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Figure 1 Study algorithm. BCM, body composition monitoring.anti-hypertensive medication and diuretics; 2) physical
examination of all body systems; 3) measurement of
height and weight with an empty abdomen; and 4) BP and
pulse rate measurement. Participants who meet all of the
inclusion and exclusion criteria and who provide written
informed consent will be eligible for this study.
Inclusion and exclusion criteria
Inclusion criteria were: age between 20 and 75 years;
duration of PD (automated peritoneal dialysis (APD)
or continuous ambulatory peritoneal dialysis (CAPD))
>4 weeks; daily urine output >500 ml; and provision of
written informed consent.
Exclusion criteria were: contraindication to bioimpe-
dance measurement (amputation, presence of pacemaker,
defibrillator, prosthesis, or metal implants); probable
discontinuation of PD or receipt of kidney transplant
within 1 year; hypoalbuminemia (serum albumin <3.3
g/dl); severe heart failure (New York Heart Association
Functional Classification (NYHA FC) III or IV); com-
bined dialysis modality (PD + intermittent hemodialysis
(HD)); pregnancy, lactation; enrollment in other clinical
trials within 1 month; uncontrolled hypertension (>160/
100 mmHg with more than three anti-hypertensive medi-
cations); cardiovascular diseases (cerebral infarction,
hemorrhagic infarction, acute myocardial infarction, or
unstable angina) and acute infection (pneumonia, peri-
tonitis) within 3 months prior to the trial.
Serum and urine creatinine (Cr) will be measured by
the isotope dilution mass spectrometry-traceable method
using a TBA 200FR Analyzer (Toshiba, Tokyo, Japan).
GFR will be calculated as the average Cr and urea clear-
ance, which is measured by urine collection [8].is with urine output > 500 ml/d
eligibility 
Excluded
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The randomization process will be conducted using a
web-based computer program. A list of random numbers
will be generated by a computerized random allocation
system operated by the Medical Statistics Support Team
in Seoul National University Hospital. Eligible partici-
pants will be randomly assigned 1:1 to either the control
group (fluid management based on the clinical informa-
tion alone) or treatment group (BIS-guided fluid manage-
ment along with clinical information). Randomization
will be stratified based on the institution and presence of
diabetes mellitus, and will utilize a randomized block
design.
Outcome measures
The primary outcome is the change in GFR between
months 0 and 12 after starting treatment. The second-
ary outcomes will include GFR measured by urine
collection, calculated by the mean of the Cr and urea
clearance at month 12; time to the anuric state (urine
volume <100 ml/day); and fatal and nonfatal cardiovascu-
lar events, including acute myocardial infarction, stroke,
unstable angina, and cardiovascular revascularization.
Parameters obtained by echocardiographic measurements,
such as the left ventricular mass index, E/e′ ratio, left ven-
tricular end-diastolic pressure, left ventricular ejection
fraction, left atrial volume index, and BP at month 12;
parameters measured by BIS, such as the OH value, ECW,
and ECW/ICW; hospitalization, cardiovascular and all-
cause mortality, and transfer to HD over the course of
1 year; pulse wave velocity (PWV), type and number
of PD fluid and diuretics at month 12, and laboratory
findings including high-sensitivity C-reactive protein (hs-
CRP), N-terminal prohormone of brain natriuretic
peptide, and cardiac troponin T, will also be evaluated as
tertiary outcomes.
Assessment of the fluid status
For participants in the control group, clinical informa-
tion obtained by physician physical examination is the
standard of judgment. Clinical information is composed
of four items, including measured BWT within 2 kg of
the dry weight, BP less than 140/90 mmHg, absence of
symptoms and signs for hypervolemia (dyspnea, edema,
and crackle) or hypovolemia (dizziness and orthostatic
hypotension).
For participants in the treatment group, the OH value
measured by the Body Composition Monitor (BCM)
(Fresenius, Medical Care Korea, Seoul, Korea), using an al-
ternating current at 50 different frequencies (5–1000 kHz)
combined with clinical information, represents the stand-
ard of judgment. The OH value is calculated using the
BCM based on a physiologic tissue model that is com-
posed of the individual’s normal ECW, normohydratedlean and adipose tissue. The OH value can be calculated
from the difference between the normal expected ECW
and the measured ECW [9]. The BCM has been validated
with isotope dilution methods against all available gold-
standard methods in the healthy population and in
patients on dialysis [10-12].
Physician’s practical treatment guidelines according to
the volume status
The target BWT will be within 1 liter of the dry BWT.
After randomization, participants in the control group
will undergo BCM measurement at the beginning and
end of the study. Both the physicians and participants
will be blinded to the results. The physicians will pre-
scribe PD solutions, drugs, and diet based on the clinical
information that they obtain. Participants in the treat-
ment group will undergo BCM measurement every
2 months over a 1-year period. Both the physicians and
the participants will be notified of the results. Based on
the BCM results combined with the clinical information,
the physicians will prescribe PD solutions, diuretics, and
diets. Figures 2 and 3 show the management of hypervo-
lemia and hypovolemia, respectively.
Participants who switch to HD or combined dialysis
(PD with intermittent HD), receive kidney transplant-
ation, transfer to other institutions, or die during the
study will be dropped out of the study. Investigators or
research coordinators will evaluate treatment adherence
and give scores for each particular item, including 1)
percentage of self-reported medical records >80%, 2)
percentage receiving PD solutions >80%, 3) adherence to
examinations including complete blood count (CBC),
chemistry, peritoneal equilibrium test, Kt/V (where K is
dialyzer clearance of urea, t is dialysis time, and V is vol-
ume of distribution of urea, approximately equal to the
patient's total body water), and 4) adherence to the
scheduled visits.
Clinical and laboratory evaluations
Physical examination, medication reviews including PD
solutions, fluid balance evaluation (semi-quantitative
scale),. and laboratory evaluations, including CBC, elec-
trolytes, Cr, protein, albumin, calcium, phosphorous, and
fasting glucose will be conducted every 2 months.
Laboratory evaluations, including total cholesterol, tri-
glyceride, low-density lipoprotein cholesterol, hs-CRP,
hemoglobin A1C, intact parathyroid hormone, N-
terminal prohormone of brain natriuretic peptide, car-
diac troponin T, and weekly Kt/Vurea, will be performed
at months 0 and 12 of treatment. Echocardiography will
be performed, and PWV will be measured using a Colin
pulse waveform analyzer (Colin CO, Ltd, Komaki, Japan)
at months 0 and 12 after treatment. The study schedule
is shown in Table 1.
> +1L from dry weight in CAPD/APD patients 
Proper diet and use of 
diuretics?
Possible to prescribe 
Icodextrin?
Yes
Use of 2.5% dextrose 
solution?
No
Low salt diet (daily dietary Na < 80mmol/d)
Titrate diuretics 




Prescribe or increase number of 2.5% dextrose solution 
Change to APD/increase frequency and decrease duration of cycler in night time exchanger
Yes
Figure 2 Hypervolemia management flow chart. APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis.
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The BIS method approved by the US Food and Drug
Administration has been used in clinical practice, par-
ticularly in Europe. Weak alternating currents into the
body are known to be not harmful.
Sample size calculations
No previous report has evaluated the effect of BIS-guided
fluid management on RRF in patients on PD. We there-
fore referred to a study showing that GFR changes over
1 year in a conventional PD solution treatment group and
in a biocompatible PD solution treatment group were
−16.8 ± 19.9 and 0.09 ± 40.9 l/week/1.73 m2, respectively
[13]. We adjusted the sample size for an estimated drop-



















Figure 3 Hypovolemia management flow chart. APD, automated peritoof significance of α = 5%, and a power of 80%, and found
that 69 participants will be required in each group to find
a significant difference using Student’s t-test. A total of
138 participants will be included in the analysis.
Statistical analyses
The statistical analyses will be conducted both on a per-
protocol (PP) and an intention-to treat (ITT) basis. For
PP analysis, all participants who complete the study will
be included to evaluate the primary and secondary out-
comes. For the ITT analysis, all participants who are
enrolled and randomized to one of the two groups and
who complete the first visit will be included.
Basic statistics will be reported in terms of mean ± SD
for continuous variables, or as percentages for categoricaluce diuretics up to 50%
ch from Icodextrin to 1.5 % dextrose solution 
nge to 1.5 % dextrose solution
nd duration of each cycle at the night time by 30 minutes
neal dialysis; CAPD, continuous ambulatory peritoneal dialysis.
Table 1 Data collection schedule of the COMPASS study
Parameter Visit time (months)
−1 0 2 4 6 8 10 12
Demographic information X
Charlson Comorbidity Index X
Physical examination1 X X X X X X X X
Medication review2 X X X X X X X X
Routine laboratory data3 X X X X X X X
Special laboratory data4 X X
RRF, urine volume X X
Compliance X X X X X X X
New events5 X X X X X X X
BCM measurement
Treatment group X X X X X X X
Control group X X
Kt/V X X
Peritoneal equilibration test X
PWV X X
Echocardiography X X
PD solution, medication change X X X X X X X
BCM, Body composition monitoring; COMPASS, Control Of fluid balance
guided by body composition Monitoring in patients on PeritoneAl dialySiS
trial; Kt/V, Calculated using single pool equation; PD, Peritoneal dialysis; PWV,
Pulse wave velocity; RRF, Residual renal function.
1Includes body weight with an empty abdomen, blood pressure, pulse rate,
and edema.
2Number of anti-hypertensive medications and diuretics and the type of
PD solution.
3Complete blood count, electrolyte, serum creatinine, protein, albumin,
calcium, phosphorous, and fasting glucose.
4Total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-
sensitivity C-reactive protein, hemoglobin A1C, intact parathyroid hormone,
N-terminal prohormone of brain natriuretic peptide, and cardiac troponin T.
5Any new clinical event, including hospitalization and peritonitis, will be
recorded during the study period.
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using Student’s t-test for continuous variables and the
χ2 test or Fisher’s exact test for categorical variables.
The difference in GFR between month 0 and month 12
will be compared between the two groups using
Student’s t-test for the primary outcome. Analysis of
covariance (ANCOVA) will be used to analyze the
primary outcome as the secondary analysis to adjust
the baseline value. Multivariate Cox proportional haz-
ard regression models will be used to analyze the time
to development of anuria. Although the institutions
are mainly located in large cities, thereby limiting the
likelihood of any important cluster effect, we will be
sure to accommodate possible clustering in our models
and analysis as required. A value of P < 0.05 will be
considered statistically significant. All analyses will be
performed using SPSS Statistics software (v21.0; IBM
Corporation, Armonk, NY, USA).Ethics approval
The study will be performed in accordance with the
Declaration of Helsinki, as amended by the 59th World
Medical Association General Assembly in 2008. All the
participants will provide signed, informed, written con-
sent, stating that participation is voluntary and can be
withdrawn at any time. Approval for the study has been
obtained from the institutional review board of Seoul
National University Bundang Hospital (E-1303/194-
001), Seoul National University Hospital (H-1302-050-
465), Seoul National University Boramae Medical
Center (16-2013-30), Gachon University Gil Hospital
(GAIRB2013-119), and Wonju Severance Christian Hos-
pital (CR312065). The trial protocol has been registered
at http://www.clinicaltrials.gov (NCT01887262).
Discussion
Preservation of RRF has been shown to be associated
with a reduction in mortality, and has become one of the
prime objectives in the treatment of patients on PD
[14,15]. Controversy remains about whether hypervole-
mia or strict volume control helps preserve RRF in these
patients [3,16,17]. Other groups have reported that BIS
may be superior to clinical information in the assessment
of fluid status for patients on HD or PD [2,9,12,18]. How-
ever, no studies have evaluated the effect of regular and
serial BIS-guided fluid management on RRF in patients
receiving PD. To our knowledge, this is the first multi-
center, prospective, randomized controlled trial assessing
whether BIS-guided volume management attenuates the
loss of RRF. The endpoints of the COMPASS (Control
Of fluid balance guided by body composition Monitoring
in patients on PeritoneAl dialySiS) study are of the ut-
most importance to healthcare providers.
The strength of the study is that only subjects who are
on PD for more than 1 month are eligible. This criterion
reduces the likelihood of a pre-dialytic uremic factor
confounding the primary outcome. Potential covariates,
such as, the differences in treatment strategies between
physicians, can also be minimized because physicians
will prescribe PD solutions, diuretics, and diet according
to the same protocol. Therefore, it is reasonable that the
type and number of PD solutions and diuretics should
serve as the secondary outcomes.
The OH value has been widely used in the assessment
of volume status in patients on PD[19-21]. Additionally,
O’Lone et al. recently reported the clinical significance of
the OH index, − an accurate value of overhydration that
was an independent predictor of mortality in contrast to
the ECW/total body water (TBW) [22]. Different BIS pa-
rameters, such as ECW/TBW, ECW normalized for
height, the OH value, and tissue hydration, have been
used as indices of hydration in previous studies [6,9,10].
In other words, there is no definite BIS parameter for
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ness and relevance of BIS various parameters will be de-
termined in the present study.
Based on normal hydration being defined as ECW
within ±1.1 liter of the 10th to the 90th percentiles in
healthy subjects [10], previous studies for patients on HD
have applied the same criteria [23-25]. Although some
studies have suggested cutoff thresholds for the definition
of the OH in patients on HD and patients on PD of 2.5
and 2.0 liters, respectively [19,26,27], we consider an
ECW within ±1.1 liter as normal hydration.
There is a chance that patients within the same institu-
tion will be more correlated than patients between insti-
tutions. To avoid this, we will investigate for possible
clustering of patients at the recruitment institution level,
and will accommodate such clustering in our models and
analysis as required. We also conservatively calculate the
sample size, assuming a high drop-out rate, to overcome
this potential problem.
A limitation of this study is that we will include both
prevalent and incident patients on PD. Although a study
targeting only incident patients on PD might provide
more solid results, we will adjust the dialysis vintage in
the multivariable analyses.
In summary, the COMPASS study is the first prospect-
ive, randomized controlled trial to evaluate the clinical
usefulness of BIS-guided fluid management in patients
on PD. The aim of this study is to evaluate whether BIS-
guided fluid management has a beneficial effect on the
decline of RRF, cardiac parameters, and cardiovascular
outcomes.
Trial status
This trial is ongoing. Participants are currently being
recruited.
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